Clinical Trial

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to control the disease.
Trial Details
NCT Number NCT07646821
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: PharmaEssentia
Conditions Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
Enrollment 30 participants
Start Date 2026-11-27
Primary Completion 2028-12-11 (estimated)
Study Completion 2030-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-15